Jörg Ruof

1.8k total citations
67 papers, 1.4k citations indexed

About

Jörg Ruof is a scholar working on Economics and Econometrics, Rheumatology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jörg Ruof has authored 67 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Economics and Econometrics, 21 papers in Rheumatology and 12 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jörg Ruof's work include Health Systems, Economic Evaluations, Quality of Life (41 papers), Rheumatoid Arthritis Research and Therapies (21 papers) and Pharmaceutical Economics and Policy (19 papers). Jörg Ruof is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (41 papers), Rheumatoid Arthritis Research and Therapies (21 papers) and Pharmaceutical Economics and Policy (19 papers). Jörg Ruof collaborates with scholars based in Germany, Switzerland and United States. Jörg Ruof's co-authors include Gerold Stucki, Sonja Merkesdal, H. Zeidler, Wilfried Mau, Thomas Mittendorf, G. Stucki, Charalabos‐Markos Dintsios, J.-Matthias Graf von der Schulenburg, Friedrich Wilhelm Schwartz and O. Sangha and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of the Rheumatic Diseases and International Journal of Obesity.

In The Last Decade

Jörg Ruof

64 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jörg Ruof Germany 21 635 401 197 188 160 67 1.4k
Polina Putrik Netherlands 22 590 0.9× 219 0.5× 309 1.6× 219 1.2× 236 1.5× 70 1.3k
Sonja Merkesdal Germany 18 628 1.0× 173 0.4× 197 1.0× 185 1.0× 141 0.9× 46 1.1k
J. Michael Woolley United States 21 407 0.6× 230 0.6× 410 2.1× 243 1.3× 76 0.5× 42 1.5k
Marieke Voshaar Netherlands 20 1.4k 2.2× 136 0.3× 293 1.5× 634 3.4× 225 1.4× 46 2.1k
S Vasoo Singapore 15 313 0.5× 167 0.4× 239 1.2× 75 0.4× 69 0.4× 29 915
Mary M. Hunter United States 6 270 0.4× 192 0.5× 48 0.2× 96 0.5× 99 0.6× 14 771
Mona L. Martin United States 15 408 0.6× 99 0.2× 48 0.2× 72 0.4× 112 0.7× 43 1.1k
Ailsa Bosworth United Kingdom 14 635 1.0× 68 0.2× 142 0.7× 292 1.6× 94 0.6× 47 922
G Kraag Canada 18 1.3k 2.0× 103 0.3× 282 1.4× 452 2.4× 60 0.4× 31 1.9k
Barry E. Koehler Canada 11 940 1.5× 107 0.3× 588 3.0× 74 0.4× 69 0.4× 20 1.6k

Countries citing papers authored by Jörg Ruof

Since Specialization
Citations

This map shows the geographic impact of Jörg Ruof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörg Ruof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörg Ruof more than expected).

Fields of papers citing papers by Jörg Ruof

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörg Ruof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörg Ruof. The network helps show where Jörg Ruof may publish in the future.

Co-authorship network of co-authors of Jörg Ruof

This figure shows the co-authorship network connecting the top 25 collaborators of Jörg Ruof. A scholar is included among the top collaborators of Jörg Ruof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörg Ruof. Jörg Ruof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mölken, Maureen Rutten‐van, Bernhard Wörmann, Daniel Widmer, et al.. (2025). Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy. Journal of Market Access & Health Policy. 13(1). 6–6.
2.
Mol, Peter G. M., Walter Van Dyck, Anja Schiel, et al.. (2024). Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy. Health Research Policy and Systems. 22(1). 74–74. 7 indexed citations
3.
Solà-Morales, Oriol, Mondher Toumi, Heiner C. Bucher, et al.. (2022). Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European Access Academy. Health Economics Review. 12(1). 54–54. 7 indexed citations
4.
Solà-Morales, Oriol, et al.. (2022). How can a joint European health technology assessment provide an ‘additional benefit’ over the current standard of national assessments?. Health Economics Review. 12(1). 30–30. 17 indexed citations
5.
6.
Giuliani, Giovanni, et al.. (2019). PDG84 REVIEW OF RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) AT THE EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT (EUNETHTA). Value in Health. 22. S611–S611. 1 indexed citations
7.
Walter, Miriam, et al.. (2018). “Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations. Health Economics Review. 8(1). 23–23. 10 indexed citations
8.
Gyldmark, Marlene, et al.. (2018). IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE. International Journal of Technology Assessment in Health Care. 34(5). 458–463. 13 indexed citations
9.
Giuliani, Giovanni, et al.. (2018). Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view. Health Economics Review. 8(1). 24–24. 8 indexed citations
10.
Ruof, Jörg, et al.. (2017). Different Weights of the Evidence-Based Medicine Triad in Regulatory, Health Technology Assessment, and Clinical Decision Making. Pharmaceutical Medicine. 31(4). 213–216. 20 indexed citations
11.
Ruof, Jörg, et al.. (2014). Dilemma of Cross-Over Trials and Their Impact on Benefit Assessment In Oncology. Value in Health. 17(7). A658–A658. 1 indexed citations
12.
Ruof, Jörg, Charalabos‐Markos Dintsios, & Friedrich Wilhelm Schwartz. (2012). PHP148 Early Benefit Assessment (EBA) in Germany: Differences Between Pharmaceutical Companies' Claims and IQWiG Benefit Assessments. Value in Health. 15(7). A315–A315. 1 indexed citations
13.
Kirchhoff, T., Jörg Ruof, Thomas Mittendorf, et al.. (2010). Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings. Lara D. Veeken. 50(4). 756–761. 27 indexed citations
14.
Borchers, Michael T., et al.. (2006). Content comparison of health status measures for obesity based on the international classification of functioning, disability and health. International Journal of Obesity. 30(12). 1791–1799. 37 indexed citations
15.
Mittendorf, Thomas, et al.. (2003). Implementing standardized cost categories within economic evaluations in musculoskeletal diseases. The European Journal of Health Economics. 4(1). 43–49. 20 indexed citations
16.
Ruof, Jörg, et al.. (2003). Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. Annals of the Rheumatic Diseases. 62(6). 544–549. 77 indexed citations
17.
Merkesdal, Sonja, Jörg Ruof, Thomas Mittendorf, H. Zeidler, & Wilfried Mau. (2002). Indirect medical costs in the first 3 years of rheumatoid arthritis: comparison of current methodological approaches. Expert Review of Pharmacoeconomics & Outcomes Research. 2(4). 313–318. 11 indexed citations
18.
Ruof, Jörg, et al.. (2002). Diffusion of innovations: treatment of Alzheimer's disease in Germany. Health Policy. 60(1). 59–66. 37 indexed citations
19.
20.
Ruof, Jörg & G. Stucki. (1999). Comparison of the Dougados Functional Index and the Bath Ankylosing Spondylitis Functional Index. A literature review.. PubMed. 26(4). 955–60. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Polina Putrik Breakdown of academic impact, for papers by Sonja Merkesdal Breakdown of academic impact, for papers by J. Michael Woolley Breakdown of academic impact, for papers by Marieke Voshaar Breakdown of academic impact, for papers by S Vasoo Breakdown of academic impact, for papers by Mary M. Hunter Breakdown of academic impact, for papers by Mona L. Martin Breakdown of academic impact, for papers by Ailsa Bosworth Breakdown of academic impact, for papers by G Kraag Breakdown of academic impact, for papers by Barry E. Koehler
Rankless by CCL
2026